we describe the successful arylation of unactivated alkanes with heteroarenes by using iridium polypyridyl complexes as the photocatalyst and persulfate as the HAT catalyst precursor under visible-light irradiation. This reaction features good functional group tolerance and broad scope with regard to both alkane and heteroarene substrates (37 examples), which allows direct access to alkyl-substituted
作者:Jeremy M. Lear、J. Quentin Buquoi、Xin Gu、Kui Pan、Darsheed N. Mustafa、David A. Nagib
DOI:10.1039/c9cc03498f
日期:——
A unified strategy enables multi-component radical addition cascades to couple alkenes, heteroarenes, and various radicals, including N3, P(O)R2, and CF3.
The invention provides 4-substituted aryl-5-hydroxyisoquinolinone derivatives and their pharmacologically acceptable addition salts with excellent inhibitory effect on poly (ADP-ribose) synthetase.
4-Substituted aryl-5-hydroxyisoquinolinone derivatives, represented by a general formula (1)
and their pharmacologically acceptable addition salts.
The invention provides 4-substituted aryl-5-hydroxyisoquinolinone derivatives and their pharmacologically acceptable addition salts with excellent inhibitory effect on poly (ADP-ribose) synthetase.
4-Substituted aryl-5-hydroxyisoquinolinone derivatives, represented by a general formula (1)
and their pharmacologically acceptable addition salts.
Regression of Established Atherosclerotic Plaques, and Treating Sudden-Onset Asthma Attacks, using PARP Inhibitors
申请人:Boulares Hamid A.
公开号:US20110028420A1
公开(公告)日:2011-02-03
A method is disclosed for treating and inducing the regression of established atherosclerotic plaques. A method is disclosed for treating asthma, including treatment of an ongoing asthma attack. In both cases, treatment with PARP inhibitors, such as the PARP inhibitor TIQ-A (Thieno[2,3-c]isoquinolin-5-one), can lead to regression of existing disease and symptoms.